C30-NBOMe
Pharmaceutical compound
From Wikipedia, the free encyclopedia
C30-NBOMe, or 30C-NBOMe, also known as N-(3,4,5-trimethoxybenzyl)-4-chloro-2,5-dimethoxyphenethylamine or as 25C-NB345OMe, is a serotonin receptor modulator of the phenethylamine, 2C, and 25-NB (NBOMe) families.[1][2][3] It is an analogue of 25C-NBOMe with three methoxy groups on the benzyl ring, located at the 3, 4, and 5 positions.[1][2][3][4] The drug was encountered as a novel designer drug in Sweden in 2013.[4][1] However, C30-NBOMe showed greater than or equal to 1,000-fold lower potency as a serotonin 5-HT2A receptor agonist in vitro compared to conventional 25-NB drugs like 25I-NBOMe and 25B-NBOMe (EC50 = 1,251 nM vs. 0.40–1.2 nM, respectively).[3] Its affinity for the serotonin 5-HT2A receptor was similarly low (Ki = 515 nM, versus 0.82 nM for 25C-NBOMe).[5] The chemical identification of C30-NBOMe has been studied and described.[2][6][7]
- None
| Clinical data | |
|---|---|
| Other names | N-(3,4,5-Trimethoxybenzyl)-4-chloro-2,5-dimethoxyphenethylamine; 25C-NB345OMe; 30C-NBOMe |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H26ClNO5 |
| Molar mass | 395.88 g·mol−1 |
| 3D model (JSmol) | |
| |
| |